Last reviewed · How we verify
Raltegravir, tenofovir/emtricitabine
This combination inhibits HIV replication by blocking integrase (raltegravir) and reverse transcriptase (tenofovir/emtricitabine) at different stages of the viral lifecycle.
This combination inhibits HIV replication by blocking integrase (raltegravir) and reverse transcriptase (tenofovir/emtricitabine) at different stages of the viral lifecycle. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients, HIV-1 infection as part of combination antiretroviral therapy.
At a glance
| Generic name | Raltegravir, tenofovir/emtricitabine |
|---|---|
| Sponsor | University of California, San Francisco |
| Drug class | Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors) |
| Target | HIV integrase, HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Raltegravir is an integrase strand transfer inhibitor (INSTI) that prevents HIV DNA from integrating into the host genome. Tenofovir is a nucleotide reverse transcriptase inhibitor and emtricitabine is a nucleoside reverse transcriptase inhibitor; together they block reverse transcription of viral RNA into DNA. This triple-mechanism approach provides potent suppression of HIV replication.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
- HIV-1 infection as part of combination antiretroviral therapy
Common side effects
- Nausea
- Diarrhea
- Headache
- Renal impairment (tenofovir-related)
- Bone density loss (tenofovir-related)
- Lactic acidosis (rare)
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Post-Exposure Prophylaxis in Health Care Workers (PHASE4)
- Research on the Psychological Status of Patients With HIV-1 Infection
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: